



A Magyar Diabetes Társaság XVIII. Kongresszusa

Somogyi Award 2006.

[www.diabet.hu]

Geremia B. Bolli

Prof. Geremia Bolli graduated from the Perugia University School of Medicine in 1972. After training in cardiology and internal medicine at the Pisa and Perugia University Schools of Medicine, respectively, Prof. Bolli trained in Endocrinology at Mayo Clinic between in 1982-83 under the guidance of Dr. John E. Herich. After we went back to University of Perugia where he currently is Professor of Medicine.

Prof. Bolli has served in scientific societies (Honorary Secretary and Vice-President of the European Society for Clinical Investigation, Associate and Deputy-in-Chief Editor for Diabetologia), he is currently member of several societies, including the European Association for the Study of Diabetes and American Diabetes Association. Prof. Bolli has been awarded with the Morgagni Prize, University of Padova, 1985; the BCL Award, British Association of Clinical Biochemists, Glasgow, 1986; Camillo Golgi Prize, European Association for the Study of



Diabetes. Lisbon, 1989; Mary Jane Kugel Award, Juvenile Diabetes Foundation International, New York, 1999; Novartis Award in Diabetes for Long-standing Achievement, Philadelphia, 2001; and the Paulescu Prize, International Diabetes Federation, Paris, 2003.

Prof. Bolli's interest in research has initially been methodology and clinical significance of measurement of glycosylated haemoglobin, and later physiology of glucose counterregulation to hypoglycaemia and pathophysiology of hypoglycaemia in Type 1 and Type 2 diabetes mellitus. At the same time, he has studied pharmacokinetics and pharmacodynamics of insulin preparations, including rapid- and long-acting insulin analogues, and set up models of intensive insulin therapy for treatment of Type 1 and Type 2 diabetes mellitus. The present interest of Prof. Bolli is long-term optimization of glycaemic control in Type 1 and Type 2 diabetes mellitus. In Type 1, Prof. Bolli is currently developing strategies to near-normalize blood glucose along with identification, treatment and prevention of hypoglycaemia and hypoglycaemia unawareness. In Type 2 diabetes, Prof. Bolli is engaged with use of insulin in an early phase of disease.